22 research outputs found
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery
followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience
relapses with a median progression-free survival of 12–18 months. There remains an urgent need for novel targeted
therapies to improve clinical outcomes in ovarian cancer. Of the many targeted therapies currently under evaluation,
the most promising strategies developed thus far are antiangiogenic agents and Poly(ADP-ribose) polymerase
(PARP) inhibitors. Particularly, PARP inhibitors are active in cells that have impaired repair of DNA by the homologous
recombination (HR) pathway. Cells with mutated breast related cancer antigens (BRCA) function have HR deficiency,
which is also present in a significant proportion of non-BRCA-mutated ovarian cancer (“BRCAness” ovarian cancer).
The prevalence of germline BRCA mutations in EOC has historically been estimated to be around 10–15 %. However,
recent reports suggest that this may be a gross underestimate, especially in women with high-grade serous ovarian
cancer (HGSOC).
Main body of the abstract: The emergence of the DNA repair pathway as a rational target in various cancers led
to the development of the PARP inhibitors. The concept of tumor-selective synthetic lethality heralded the beginning
of an eventful decade, culminating in the approval by regulatory authorities both in Europe as a maintenance
therapy and in the United States treatment for advanced recurrent disease of the first oral PARP inhibitor, olaparib, for
the treatment of BRCA-mutated ovarian cancer patients. Other PARP inhibitors are clearly effective in this disease and,
within the next years, the results of ongoing randomized trials will clarify their respective roles.
Conclusion: This review will discuss the different PARP inhibitors in development and the potential use of this
class of agents in the future. Moreover, combination strategies involving PARP inhibitors are likely to receive increasing
attention. The utility of PARP inhibitors combined with cytotoxic chemotherapy is of doubtful value, because of
enhanced toxicity of this combination; while, more promising strategies include the combination with antiangiogenic
agents, or with inhibitors of the P13K/AKT pathway and new generation of immunotherapy
From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors
In recent years, significant progress has been made in the diagnosis and treatment of gastrointestinal cancers. Researches and clinicians however are still faced with challenges, not the least is the detection and management of tumors with varied gene mutation status. Clarification of the molecular pathology of gastrointestinal cancers may improve treatment options as well as quality of life and the long-term survival of this patient class. Therefore, molecular-targeted therapies have emerged as clinically useful drugs for gastrointestinal cancers cure, and predictive biomarkers have been heralded as the way to develop the right drug for the right patient. Moving from such appealing molecular background, we wrote an overview of the main targeted therapies, with particular interest to monoclonal antibodies that have already been approved in clinical practice or are being tested in gastrointestinal cancers treatment. © 2014 International Society of Oncology and BioMarkers (ISOBM)
Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases
Although surgery is the most effective treatment for liver metastases in colorectal cancer patients, only 15-20% of these patients are suitable for a radical surgical approach, and metastases recurrence may occur at follow up. In the last decade, the use of pre-operative chemotherapy in combination with new biological drugs has been introduced. We reviewed data of neo-adjuvant chemotherapy strategies aimed at increasing the resection rate of liver metastases in colorectal cancer patients who were initially considered unresectable
Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: Basic knowledge and therapeutic possibilities for an innovative approach
In 2013 there will be an estimated 22,240 new diagnoses and 14,030 deaths from ovarian cancer in the United
States. Despite the improved surgical approach and the novel active drugs that are available today in clinical
practice, about 80% of women presenting with late-stage disease have a 5-year survival rate of only 30%. In the last
years a growing scientific knowledge about the molecular pathways involved in ovarian carcinogenesis has led to
the discovery and evaluation of several novel molecular targeted agents, with the aim to test alternative models of
treatment in order to overcome the clinical problem of resistance. Cancer stem cells tend to be more resistant to
chemotherapeutic agents and radiation than more differentiated cellular subtypes from the same tissue. In this
context the study of ovarian cancer stem cells is taking on an increasingly important strategic role, mostly for the
potential therapeutic application in the next future. In our review, we focused our attention on the molecular
characteristics of epithelial ovarian cancer stem cells, in particular on possible targets to hit with targeted therapies
Bevacizumab in ovarian cancer: a critical review of phase III studies
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC). Randomized Phase III trials evaluated the combination of BV plus standard chemotherapy for first-line treatment of advanced OC and for platinum-sensitive and platinum-resistant recurrent OC. These trials reported a statistically significant improvement in progression-free survival but not in overall survival. Furthermore, BV effectively improved the quality of life with regard to abdominal symptoms in recurrent OC patients. Bevacizumab is associated with adverse events such as hypertension, bleeding, thromboembolism, proteinuria, delayed wound healing, and gastrointestinal events. However, most of these events can be adequately managed. This review describes the latest evidence for BV treatment of OC and selection of patients for personalized treatment
Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.
Currently we are more and more improving our knowledge about the characteristics and the role of cancer stem cells in human cancer. Particularly we have realized that self-renewing ovarian cancer stem cells (CSCs) or ovarian cancer-initiating cells, and mesenchymal stem cells (SCs) too, are probably implicated in the etiopathogenesis of epithelial ovarian cancer (EOC). There is clear evidence that these cells are also involved in its intra- and extra-peritoneal diffusion and in the occurrence of chemo-resistance. In assessing the molecular characteristics of ovarian CSCs, we have to take note that these cellular populations are rare and the absence of specific cell surface markers represents a challenge to isolate and identify pure SC populations. In our review, we focused our attention on the molecular characteristics of epithelial ovarian CSCs and on the methods to detect them starting from their biological features. The study of ovarian CSCs is taking on an increasingly important strategic role, mostly for the potential therapeutic application in the next future
Breast cancer metastatic to the pituitary gland: a case report
Abstract Background Metastases to the pituitary gland are rare events, and usually indicate widespread malignant disease. The lung and the breast are the most common sites of primary tumors that metastasize to the pituitary gland. Metastases are more frequent in older patients and the most common symptoms at presentation are diabetes insipidus and visual alterations. Case presentation 72-year-old white woman was treated for a breast carcinoma with right superoexternal quadrantectomy, radiotherapy, and hormone therapy. Twelve years later, the patient presented with bone pain, bilateral progressive visual decline, and onset of hypopituitarism. A diagnosis of secondary bone involvement and pituitary metastasis was made. Conclusion This was an unusual disease course, and stresses the importance of intensive follow-up in patients with breast cancer even many years after the initial diagnosis This case emphasizes that diagnosis can be difficultand controversial when relapse occurs at uncommon sites.</p
Subcutaneous metastases from colon cancer: A case report
Introduction: Dukes A stages of colorectal cancer are rarely reported to metastasize. Subcutaneous or skin metastases from colon cancer are rare events and usually indicate widespread disease. Case presentation: We present the case of a 72-year-old Caucasian woman with Dukes A colorectal cancer at diagnosis and, three years later, a single secondary subcutaneous involvement with no other metastatic sites. The description of this case is supported by critical analysis of its clinical, radiological and pathological features. Our report illustrates that diagnosis can be difficult and controversial when relapse occurs in early stage patients and at uncommon sites. Conclusion: The unusual and aggressive course of the reported disease stresses the importance of intensive follow-up in colorectal cancer patients with good prognostic factors. © 2012 Lo-Russo et al.; licensee BioMed Central Ltd